Niklas Luhmann1, Julie Champagnat2, Sergey Golovin3, Ludmila Maistat4, Edo Agustian5, Ina Inaridze6, Wai Moe Myint7, Maia Butsashvili8, Julie Bouscaillou2. 1. Médecins du Monde France, 62 rue Marcadet, 75018, Paris, France. Electronic address: niklas.luhmann@medecinsdumonde.net. 2. Médecins du Monde France, 62 rue Marcadet, 75018, Paris, France. 3. International Treatment Preparedness Coalition in Eastern Europe and Central Asia, Dostoevskogo 38-30, St. Petersburg, Russia. 4. International HIV/AIDS Alliance in Ukraine, 5 Dymytrova St., Build 10A, 03680 Kyiv, Ukraine. 5. Indonesian Drug User Network Persaudaraan Korban Napza (PKNI), Jalan Tebet Timur Dalam XI No. 94 Tebet, Jakarta Selatan 12820, Indonesia. 6. Médecins du Monde Georgia, 46 Street, Gutani, Tbilisi, 0179, Georgia. 7. Médecins du Monde Myanmar, No (11-B) Maharmyaing Street, Sanchaung Township, Yangon, Myanmar. 8. Health Research Union, 8 Nutsubidze Str., Tbilisi 0177, Georgia.
Abstract
BACKGROUND: People who inject drugs (PWID) are disproportionately affected by the hepatitis C (HCV) epidemic. Of the estimated 16 million PWID worldwide, approximately 8 million live with chronic HCV, and around 26% and 23% of the global HCV infections among PWID occur in East/Southeast Asia and Eastern Europe respectively. Globally, few PWID have access to treatment for HCV. METHODS: We conducted a systematic literature review and internet survey in 2014 to document the burden of disease, access to diagnosis and treatment and the existence of national policy and treatment guidelines for HCV. We included Georgia, Russia, Ukraine, Myanmar and Indonesia as countries with injection drug use epidemics. FINDINGS: HCV antibody prevalence among the general population ranged from 0.80% in Indonesia to 5% in Georgia, and among PWID from 48.1% in Myanmar to 92% in Georgia. PWID carried a significant burden of disease, ranging from 2.7% in Indonesia to 40.4% in Russia. Yearly treatment uptake was under 1% for the general population and PWID in all countries. Diagnostic tools and disease staging investigations as well as pegylated interferon/ribavirin treatment were available at a range of prices. Despite policy and treatment protocols for HCV in the majority of countries, strategies focusing on PWID were largely absent. CONCLUSION: PWID are a priority group for treatment, and access to treatment should be based on sound national policy, accessible public treatment programmes and functional surveillance systems.
BACKGROUND:People who inject drugs (PWID) are disproportionately affected by the hepatitis C (HCV) epidemic. Of the estimated 16 million PWID worldwide, approximately 8 million live with chronic HCV, and around 26% and 23% of the global HCV infections among PWID occur in East/Southeast Asia and Eastern Europe respectively. Globally, few PWID have access to treatment for HCV. METHODS: We conducted a systematic literature review and internet survey in 2014 to document the burden of disease, access to diagnosis and treatment and the existence of national policy and treatment guidelines for HCV. We included Georgia, Russia, Ukraine, Myanmar and Indonesia as countries with injection drug use epidemics. FINDINGS: HCV antibody prevalence among the general population ranged from 0.80% in Indonesia to 5% in Georgia, and among PWID from 48.1% in Myanmar to 92% in Georgia. PWID carried a significant burden of disease, ranging from 2.7% in Indonesia to 40.4% in Russia. Yearly treatment uptake was under 1% for the general population and PWID in all countries. Diagnostic tools and disease staging investigations as well as pegylated interferon/ribavirin treatment were available at a range of prices. Despite policy and treatment protocols for HCV in the majority of countries, strategies focusing on PWID were largely absent. CONCLUSION: PWID are a priority group for treatment, and access to treatment should be based on sound national policy, accessible public treatment programmes and functional surveillance systems.
Authors: Olena Iakunchykova; Anna Meteliuk; Alexei Zelenev; Alyona Mazhnaya; Melissa Tracy; Frederick L Altice Journal: Int J Drug Policy Date: 2018-04-12
Authors: Alyona Mazhnaya; Anna Meteliuk; Tetiana Barnard; Alexei Zelenev; Sergii Filippovych; Frederick L Altice Journal: Int J Drug Policy Date: 2017-08-12
Authors: Maria A Corcorran; Natasha Ludwig-Baron; Debbie M Cheng; Dmitry Lioznov; Natalia Gnatienko; Gregory Patts; Kaku So-Armah; Elena Blokhina; Sally Bendiks; Evgeny Krupitsky; Jeffrey H Samet; Judith I Tsui Journal: AIDS Behav Date: 2021-03-17
Authors: Naomi Khaing Than Hlaing; Debolina Banerjee; Robert Mitrani; Soe Htet Arker; Kyaw San Win; Nyan Lin Tun; Zaw Thant; Khin Maung Win; K Rajender Reddy Journal: World J Gastroenterol Date: 2016-11-21 Impact factor: 5.742
Authors: Noemi Hernández-Alvarez; Juan Manuel Pascasio Acevedo; Enrique Quintero; Inmaculada Fernández Vázquez; María García-Eliz; Juan de la Revilla Negro; Javier Crespo García; Manuel Hernández-Guerra Journal: BMJ Open Gastroenterol Date: 2017-03-04
Authors: Daniel Fuster; Kaku So-Armah; Debbie M Cheng; Sharon M Coleman; Natalia Gnatienko; Dmitry Lioznov; Evgeny M Krupitsky; Matthew S Freiberg; Jeffrey H Samet Journal: Curr HIV Res Date: 2021 Impact factor: 1.341
Authors: Lei Zhang; Feng Cheng; Shu Su; Shunxiang Li; Shifu Li; Jun Jing; Christopher Kincaid Fairley; Liang Chen; Jinxian Zhao; Limin Mao Journal: BMJ Open Date: 2018-06-30 Impact factor: 2.692